Ion Beam Applications SA IBA ((GB:0GZK)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ion Beam Applications SA (IBA) is conducting a clinical trial titled ‘Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS for Radiation Therapy in Oncology Patients.’ This study aims to evaluate the safety and efficacy of the PROTEUS® PLUS system for treating oncology patients, providing essential data for product registration.
The intervention being tested is the PROTEUS® PLUS Proton Beam Therapy (PBT), a device designed to deliver precise radiation therapy to patients with solid tumors.
The study follows an interventional design with a single-group model. There is no allocation or masking involved, and the primary purpose is treatment. This straightforward approach focuses on assessing the treatment’s direct impact on participants.
The study began on August 1, 2025, with the latest update submitted on August 14, 2025. These dates are crucial as they mark the study’s initiation and the most recent progress report, indicating ongoing recruitment and data collection.
For investors, the successful outcome of this study could enhance IBA’s market position, potentially boosting its stock performance. The study’s progress is crucial for IBA, especially in a competitive field where advancements in radiation therapy technology can significantly influence market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.